바이오테크 보도자료
-
- Philip Morris International Acquires Inhaled Drug Specialist OtiTopic; Growing Pipeline of “Beyond Nicotine” Inhaled Therapeutic Products
- Philip Morris International Inc. (PMI) (NYSE: PM) today announced its acquisition of OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid (ASA) treatment for...
- 2021년 08월 10일
-
- Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the publication of the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-labe...
- 2021년 08월 06일
-
- Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance[1]
- Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as CO...
- 2021년 08월 05일
-
- Former World Economic Forum Member of the Managing Board Murat Sönmez Joins Avellino’s Board of Directors
- Avellino Lab USA, Inc. (Avellino) today announced the appointment of Murat Sönmez to the company’s Board of Directors. Murat is a former World Economic Forum Member of the Managing Board and founding head of...
- 2021년 08월 04일
-
- First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
- In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focu...
- 2021년 08월 03일
-
- Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissio...
- 2021년 08월 02일
-
- NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company developing a first-in-class GM-CSF neutralizing antibody to prevent and treat an immune hyper-response called ‘cytokin...
- 2021년 08월 02일
-
- ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
- ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with...
- 2021년 08월 02일
-
- Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quart...
- 2021년 08월 02일
-
- Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company t...
- 2021년 07월 30일
-
- Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology
- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger ...
- 2021년 07월 30일
전시회
